Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
No specific antivirals are currently available for two emerging infectious diseases, Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). A literature search was performed covering pathogenesis, clinical features and therapeutics, clinically developed drugs for repurposing and novel drug targets. This review presents current knowledge on the epidemiology, pathogenesis and clinical features of the SARS and MERS coronaviruses. The rationale for and outcomes with treatments used for SARS and MERS is discussed. The main focus of the review is on drug development and the potential that drugs approved for other indications provide for repurposing. The drugs we discuss belong to a wide range of different drug classes, such as cancer therapeutics, antipsychotics, and antimalarials. In addition to their activity against MERS and SARS coronaviruses, many of these approved drugs have broad-spectrum potential and have already been in clinical use for treating other viral infections. A wealth of knowledge is available for these drugs. However, the information in this review is not meant to guide clinical decisions, and any therapeutic described here should only be used in context of a clinical trial. Potential targets for novel antivirals and antibodies are discussed as well as lessons learned from treatment development for other RNA viruses. The article concludes with a discussion of the gaps in our knowledge and areas for future research on emerging coronaviruses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061 · cited 1×
“Dipeptidyl peptidase 4 (DPP4) acts as functional virus receptor [49], and cellular proteases [e.”
BackgroundInto the Eye of the Cytokine Storm
Tisoncik, J. R., Korth, M. J., Simmons, C. P., Farrar, J., Martin, T. R., & Katze, M. G. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05015-11 · Cited by 1,940
Assiri, A., Al-Tawfiq, J. A., Al-Rabeeah, A. A., Al-Rabiah, F. A., Al-Hajjar, S., Al-Barrak, A., Flemban, H., Al-Nassir, W. N., Balkhy, H. H., Al-Hakeem, R. F., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70204-4 · Cited by 1,435
Matsuyama, S., Nagata, N., Shirato, K., Kawase, M., Takeda, M., & Taguchi, F. (2010) · Journal of Virology · doi:10.1128/jvi.01542-10 · Cited by 778
Identification of a candidate therapeutic autophagy-inducing peptide
Shoji-Kawata, S., Sumpter, R., Leveno, M., Campbell, G. R., Zou, Z., Kinch, L., Wilkins, A. D., Sun, Q., Pallauf, K., MacDuff, D., et al. (2013) · Nature · doi:10.1038/nature11866 · Cited by 760
T cell-mediated immune response to respiratory coronaviruses
Channappanavar, R., Zhao, J., & Perlman, S. (2014) · Immunologic Research · doi:10.1007/s12026-014-8534-z · Cited by 512 · cited 1×
“Although clinical signs of disease, including weight loss, were limited in this model, it has been used for pathogenesis countermeasure studies [221, 222].”
MethodWang, L.-F., Shi, Z., Zhang, S., Field, H., Daszak, P., & Eaton, B. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1212.060401 · Cited by 471 · cited 1×
“During the initial outbreak, SARS-CoV was originally isolated from palm civets found in a Chinese market; but, SARS-CoV was not found in the wild palm civet population [12].”
BackgroundChannappanavar, R., Fett, C., Zhao, J., Meyerholz, D. K., & Perlman, S. (2014) · Journal of Virology · doi:10.1128/jvi.01505-14 · Cited by 411 · cited 1×
“Although clinical signs of disease, including weight loss, were limited in this model, it has been used for pathogenesis countermeasure studies [221, 222].”
MethodA monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA
Ewer, K., Rampling, T., Venkatraman, N., Bowyer, G., Wright, D., Lambe, T., Imoukhuede, E. B., Payne, R., Fehling, S. K., Strecker, T., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1411627 · Cited by 348
Tang, X.-C., Agnihothram, S. S., Jiao, Y., Stanhope, J., Graham, R. L., Peterson, E. C., Avnir, Y., Tallarico, A. S. C., Sheehan, J., Zhu, Q., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402074111 · Cited by 232
SAIJO, M., MORIKAWA, S., FUKUSHI, S., MIZUTANI, T., HASEGAWA, H., NAGATA, N., IWATA, N., & KURANE, I. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2005.01.003 · Cited by 82
Hutterer, C., Wandinger, S. K., Wagner, S., Müller, R., Stamminger, T., Zeitträger, I., Godl, K., Baumgartner, R., Strobl, S., & Marschall, M. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.04.017 · Cited by 43
Cited by
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,347
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
Zhou, Y., Hou, Y., Shen, J., Huang, Y., Martin, W., & Cheng, F. (2020) · Cell Discovery · doi:10.1038/s41421-020-0153-3 · Cited by 1,597
Wang, Y., Wang, Y., Chen, Y., & Qin, Q. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25748 · Cited by 1,531
Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., Wu, Y., Xiao, W., Liu, S., Chen, E., et al. (2020) · BMJ · doi:10.1136/bmj.m1849 · Cited by 1,135
Stawicki, S., Jeanmonod, R., Miller, A., Paladino, L., Gaieski, D., Yaffee, A., De Wulf, A., Grover, J., Papadimos, T., Bloem, C., et al. (2020) · Journal of Global Infectious Diseases · doi:10.4103/jgid.jgid_86_20 · Cited by 373
Metadata
- Authors
- Dyall, J., Gross, R., Kindrachuk, J., Johnson, R. F., Olinger, G. G., Hensley, L. E., Frieman, M. B., & Jahrling, P. B.
- Venue
- Drugs
- Published
- 2017-11-15
- Volume
- 77
- Issue
- 18
- Pages
- 1935-1966
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W2768181348
- Cited by
- 199
- References
- 14
- FWCI
- 19.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.